Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + floxuridine
- Development stage
- Phase 2
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
Cisplatin + floxuridine is a combination chemotherapy regimen used primarily for the treatment of hepatic metastases from colorectal cancer. Cisplatin is a platinum-based antineoplastic agent that forms DNA crosslinks, inhibiting DNA synthesis and function, while floxuridine is an antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase after conversion to fluorouracil or its active metabolites. The combination has been administered via hepatic arterial infusion for targeted delivery to liver tumors, resulting in improved response rates compared to systemic therapy alone[1][2][4].
- Other names
- CDDP + FUDRcisplatin and floxuridine
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + floxuridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + floxuridine.